AR035977A1 - Inmunoconjugados de anticuerpos cd44 citotoxicos. - Google Patents

Inmunoconjugados de anticuerpos cd44 citotoxicos.

Info

Publication number
AR035977A1
AR035977A1 ARP020101829A ARP020101829A AR035977A1 AR 035977 A1 AR035977 A1 AR 035977A1 AR P020101829 A ARP020101829 A AR P020101829A AR P020101829 A ARP020101829 A AR P020101829A AR 035977 A1 AR035977 A1 AR 035977A1
Authority
AR
Argentina
Prior art keywords
immunoconjugados
citotoxicos
antibodies
conjugates
antibody conjugates
Prior art date
Application number
ARP020101829A
Other languages
English (en)
Inventor
Adolf Guenther Dr
Patzelt Erik Dr
Sproll Marlies Dr
Heider Karl-Heinz Dr
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR035977A1 publication Critical patent/AR035977A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Conjugados de anticuerpos con compuestos citotóxicos, a composiciones farmacéuticas que contienen dichos conjugados, y a su uso en la terapia del cáncer. Conjugados de anticuerpos que son específicos para CD44, con maitansinoides, preferiblemente con N2'-desacetil-N2'-(3-mercapto-1-oxopropil)maitansina.
ARP020101829A 2001-05-18 2002-05-17 Inmunoconjugados de anticuerpos cd44 citotoxicos. AR035977A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01112227A EP1258255A1 (en) 2001-05-18 2001-05-18 Conjugates of an antibody to CD44 and a maytansinoid

Publications (1)

Publication Number Publication Date
AR035977A1 true AR035977A1 (es) 2004-07-28

Family

ID=8177473

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101829A AR035977A1 (es) 2001-05-18 2002-05-17 Inmunoconjugados de anticuerpos cd44 citotoxicos.

Country Status (24)

Country Link
EP (2) EP1258255A1 (es)
JP (1) JP2004529963A (es)
KR (1) KR20030097883A (es)
CN (1) CN1509187A (es)
AR (1) AR035977A1 (es)
BG (1) BG108366A (es)
BR (1) BR0209862A (es)
CA (1) CA2443438A1 (es)
CO (1) CO5550468A2 (es)
CZ (1) CZ20033477A3 (es)
EA (1) EA200301159A1 (es)
EE (1) EE200300568A (es)
HR (1) HRP20030932A2 (es)
HU (1) HUP0400046A3 (es)
IL (1) IL157965A0 (es)
MX (1) MXPA03010432A (es)
NO (1) NO20035108L (es)
NZ (1) NZ530167A (es)
PE (1) PE20021097A1 (es)
PL (1) PL365480A1 (es)
SK (1) SK15582003A3 (es)
WO (1) WO2002094325A2 (es)
YU (1) YU91503A (es)
ZA (1) ZA200307364B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
DE10256083A1 (de) * 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
CN101186613B (zh) * 2003-05-20 2014-09-17 伊缪诺金公司 含有新的美登素类的改进的细胞毒剂
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2532430C (en) * 2003-07-21 2016-12-13 Immunogen, Inc. Humanized versions of monoclonal antibody ds6 that bind tumour antigen ca6
EP3101034A1 (en) * 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
JP5421532B2 (ja) 2004-12-09 2014-02-19 セントカー・インコーポレーテツド 抗インテグリン免疫コンジュゲート、方法および使用
CA2597407C (en) * 2005-02-11 2013-09-10 Immunogen, Inc. Process for preparing stable drug conjugates
CA2600505C (en) 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
ZA200708694B (en) * 2005-04-15 2009-01-28 Immunogen Inc Elimination of heterogeneous or mixed cell population in tumors
US20060239910A1 (en) 2005-04-22 2006-10-26 Morphotek Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
RS52470B (en) * 2005-08-24 2013-02-28 Immunogen Inc. PROCEDURE FOR PREPARATION OF PURE CONJUGATED MEDICINES
EP1806365A1 (en) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
AR078471A1 (es) * 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
EA201991268A3 (ru) 2011-03-29 2020-01-31 Иммуноджен, Инк. Получение конъюгатов "майтансиноид-антитело" одностадийным способом
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
NZ707091A (en) 2012-10-04 2018-12-21 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
GB201220899D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived pegylated peptides
GB201220889D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating metastasizing cancers
GB201220901D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
GB201220891D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
CA2921412A1 (en) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
WO2016150521A1 (en) * 2015-03-26 2016-09-29 Fundación Imdea Nanociencia Functionalised magnetic nanoparticle
WO2019161528A1 (en) * 2018-02-22 2019-08-29 Abmart Shanghai Co., Ltd. Therapeutic antibody and uses thereof
CN114057874B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
DE19648209A1 (de) * 1996-11-21 1998-05-28 Boehringer Ingelheim Int Verfahren zur Tumorzelldepletion CD34-positiver Zellen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
SI2803367T1 (en) * 1999-06-25 2018-04-30 Immunogen, Inc. Treatment methods with maytansinoid conjugated antibody anti-ERBB
CA2385528C (en) * 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents

Also Published As

Publication number Publication date
NZ530167A (en) 2005-10-28
SK15582003A3 (sk) 2004-04-06
HRP20030932A2 (en) 2004-04-30
EE200300568A (et) 2004-04-15
KR20030097883A (ko) 2003-12-31
JP2004529963A (ja) 2004-09-30
YU91503A (sh) 2006-05-25
BG108366A (bg) 2004-09-30
NO20035108D0 (no) 2003-11-17
EP1395290A2 (en) 2004-03-10
EP1258255A1 (en) 2002-11-20
MXPA03010432A (es) 2004-04-02
BR0209862A (pt) 2004-06-08
WO2002094325A2 (en) 2002-11-28
CO5550468A2 (es) 2005-08-31
EA200301159A1 (ru) 2004-06-24
PE20021097A1 (es) 2003-02-13
HUP0400046A2 (hu) 2004-04-28
PL365480A1 (en) 2005-01-10
ZA200307364B (en) 2004-04-20
NO20035108L (no) 2003-11-17
HUP0400046A3 (en) 2006-02-28
IL157965A0 (en) 2004-03-28
WO2002094325A3 (en) 2003-04-17
CA2443438A1 (en) 2002-11-28
CN1509187A (zh) 2004-06-30
CZ20033477A3 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
DK1036058T3 (da) Adamantanderivater
DK1036059T3 (da) Adamantanderivater
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
DE60142342D1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
TR199802423T2 (xx) Konsantre antikor terkibi.
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DE602006016344D1 (de) Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate, die diese enthalten
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
BR0210568A (pt) Conjugado, uso de um conjugado, composição farmacêutica, e, método para tratar câncer em um mamìfero
ATE389721T1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
ATE389019T1 (de) Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
TR200100054T2 (tr) Paroksetin metansülfonat
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
EE200100366A (et) Antikehade kasutamine vähivastase farmatseutilisekompositsiooni valmistamiseks
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
ES2175798T3 (es) Cd8 como un inhibidor del sistema inmunitario celular.
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
BR0008305A (pt) Utilização de uma proteìna ompa de enterobactéria, ou de um de seus fragmentos e composição farmacêutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal